Drugs that contain Temsirolimus

1. Drug name - TORISEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8299116 PF PRISM CV CCI-779 concentrate formulations Jul, 2023

(9 months from now)

US8722700 PF PRISM CV CCI-779 formulations for parenteral administration Jul, 2023

(9 months from now)

US8455539 PF PRISM CV CCI-779 concentrate formulations Jul, 2023

(9 months from now)

US8722700

(Pediatric)

PF PRISM CV CCI-779 formulations for parenteral administration Jan, 2024

(1 year, 3 months from now)

US8299116

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations Jan, 2024

(1 year, 3 months from now)

US8455539

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations Jan, 2024

(1 year, 3 months from now)

US8026276 PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant Jan, 2026

(3 years from now)

US8026276

(Pediatric)

PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant Jul, 2026

(3 years from now)

US8791097 PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer May, 2032

(9 years from now)

US8791097

(Pediatric)

PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer Nov, 2032

(10 years from now)

Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
25MG/ML (25MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.